MedElevator
Войти в исследования Dermatology (Basel, Switzerland) · 2011
Quality of health care of rosacea in Germany from the patient's perspective: results of the national health care study Rosareal 2009.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Langenbruch A K, Beket E, Augustin M
Аннотация
OBJECTIVES: To obtain reliable data on quality of care of rosacea and to compare care indicators with those found in atopic dermatitis and psoriasis.
PATIENTS AND METHODS: In this cross-sectional study, clinical history, health-related quality of life (HrQoL), medication and treatment benefit of patients with rosacea were assessed by standardized questionnaires. Data were compared to patients with atopic dermatitis and psoriasis.
RESULTS: Almost all 475 participants (96.4%) had received topical therapy. 24% had used cortisone ointments. The mean Dermatology Life Quality Index (DLQI) was 4.3 ± 4.6 (atopic dermatitis: 8.5 ± 6.0, psoriasis: 6.7 ± 6.2). The Patient Benefit Index (patient-defined therapeutic benefit) was 1.9 ± 1.2 (psoriasis: 2.3 ± 1.1, atopic dermatitis: 2.1 ± 1.1).
CONCLUSIONS: Only a small proportion of the rosacea patients had substantial impairments in HrQoL. Overall, their burden appears to be lower than in patients with atopic dermatitis or psoriasis. However, the lower therapeutic benefit and the high proportion of topical steroid use indicate a need for optimized therapy.
PATIENTS AND METHODS: In this cross-sectional study, clinical history, health-related quality of life (HrQoL), medication and treatment benefit of patients with rosacea were assessed by standardized questionnaires. Data were compared to patients with atopic dermatitis and psoriasis.
RESULTS: Almost all 475 participants (96.4%) had received topical therapy. 24% had used cortisone ointments. The mean Dermatology Life Quality Index (DLQI) was 4.3 ± 4.6 (atopic dermatitis: 8.5 ± 6.0, psoriasis: 6.7 ± 6.2). The Patient Benefit Index (patient-defined therapeutic benefit) was 1.9 ± 1.2 (psoriasis: 2.3 ± 1.1, atopic dermatitis: 2.1 ± 1.1).
CONCLUSIONS: Only a small proportion of the rosacea patients had substantial impairments in HrQoL. Overall, their burden appears to be lower than in patients with atopic dermatitis or psoriasis. However, the lower therapeutic benefit and the high proportion of topical steroid use indicate a need for optimized therapy.